Gilead Science (GILD.US), a US biotech company gains over 10% at the start of the Wall Street session, based on information about the possible high efficacy of Remdesivir drug for coronavirus. The drug was previously used to treat other viruses, such as Eboli or SARS or MERS. According to the company, the drug is expected to significantly weaken the effect of coronavirus and lead to faster recovery of patients. Attempts to treat people infected with coronavirus with Remdesivir have been conducted on a small sample and involved people with rather mild symptoms, so scientists are asking to refrain from euphoria regarding the effectiveness of this drug.
Gilead is opening up with a large bullish gap. Source: xStation5